| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TREML1 |
| Uniprot No | Q86YW5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 16-162aa |
| 氨基酸序列 | QGIVGSLPEVLQAPVGSSILVQCHYRLQDVKAQKVWCRFLPEGCQPLVSS AVDRRAPAGRRTFLTDLGGGLLQVEMVTLQEEDAGEYGCMVDGARGPQIL HRVSLNILPPEEEEETHKIGSLAENAFSDPAGSANPLEPSQDEKSIPVDH HHHHH |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TREML1重组蛋白的3篇参考文献及其简要摘要：
---
1. **文献名称**：*"Recombinant TREM-like transcript 1 protein protects against LPS-induced septic shock in mice"*
**作者**：Chen, Q., Zhang, Y., Li, S., et al.
**摘要**：该研究通过大肠杆菌系统表达并纯化了TREML1重组蛋白，发现其能够抑制LPS诱导的小鼠巨噬细胞炎症反应，显著降低脓毒症模型小鼠的死亡率，提示TREML1可能通过负调控TLR4信号通路发挥抗炎作用。
---
2. **文献名称**：*"Characterization of soluble TREML1 as a potential biomarker for atherosclerosis"*
**作者**：Wang, L., Liu, X., Zheng, H., et al.
**摘要**：作者利用哺乳动物细胞(HEK293)系统表达可溶性TREML1重组蛋白，发现其在动脉粥样硬化患者血清中水平升高。体外实验表明该蛋白可结合血管内皮细胞表面受体，促进单核细胞黏附，提示其可能参与动脉粥样硬化进展。
---
3. **文献名称**：*"Expression and functional analysis of recombinant TREML1 in modulating platelet activation"*
**作者**：Garcia, R., Thompson, E.J., Patel, A.
**摘要**：研究通过杆状病毒-昆虫细胞系统高效表达TREML1重组蛋白，发现其能够抑制凝血酶诱导的血小板聚集和P-选择素释放，表明TREML1可能在血栓形成调控中具有潜在治疗价值。
---
**注**：以上文献信息为示例性内容，实际文献需通过PubMed、Web of Science等数据库检索确认。若需具体文章，建议以“TREML1 recombinant protein”为关键词进一步筛选近年研究。
TREM-like transcript 1 (TREML1) is a cell surface receptor belonging to the triggering receptor expressed on myeloid cells (TREM) family, which plays critical roles in innate immune responses. Located on chromosome 6 in humans, TREML1 is primarily expressed on myeloid cells, including monocytes, macrophages, and dendritic cells, and interacts with adaptor proteins like DAP12 to mediate intracellular signaling. It regulates inflammatory processes by modulating cytokine production and cell activation, with studies linking it to atherosclerosis, sepsis, and autoimmune disorders.
Recombinant TREML1 protein refers to the engineered form of this receptor produced in vitro using expression systems like *E. coli*, yeast, or mammalian cells. This purified protein retains functional domains, such as the extracellular immunoglobulin-like region critical for ligand binding, enabling researchers to study its structure, interactions, and signaling mechanisms. Recombinant TREML1 is widely used in biochemical assays, ligand-receptor binding studies, and antibody development. It also serves as a tool to explore therapeutic targeting, as aberrant TREML1 activity is implicated in chronic inflammation and disease progression.
Current research focuses on clarifying TREML1’s ligands and downstream pathways, as well as its dual role in pro- and anti-inflammatory responses depending on context. Challenges include understanding tissue-specific regulation and reconciling conflicting data from different disease models. Recombinant protein-based studies remain pivotal for advancing diagnostic and therapeutic strategies, particularly in immune-mediated diseases.
×
